Exchange: NASDAQ·Updated 11:12 PM EDT
HUMA logo

HUMAHumacyte Inc

$0.781
$0.0179
(2.24%)
Overnight
Prev Close $0.7989
EarningsAug 10
Mkt Cap$191.07M
Vol36.76M
News
all
press releases
Here's Why Humacyte, Inc. (HUMA) Fell More Than Broader Market
Humacyte, Inc. (HUMA) concluded the recent trading session at $0.62, signifying a -11.14% move from its prior day's close.
Zacks
News Placeholder
More News
News Placeholder
Brokers Suggest Investing in Humacyte, Inc. (HUMA): Read This Before Placing a Bet
The average brokerage recommendation (ABR) for Humacyte, Inc. (HUMA) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
Zacks
News Placeholder
Humacyte, Inc. (HUMA) Dips More Than Broader Market: What You Should Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $1.03, moving 3.74% from the previous trading session.
Zacks
News Placeholder
Humacyte, Inc. (HUMA) Upgraded to Buy: Here's What You Should Know
Humacyte, Inc. (HUMA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks
News Placeholder
HUMA Stock Plunges After-Hours On Proposed Share Offering Even As Dialysis Data Impresses
The size and price of the stock offering were not disclosed.
Stocktwits
News Placeholder
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? Did Humacyte, Inc. Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, June 5, 2026 Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We...
PR Newswire
News Placeholder
Wall Street Bulls Look Optimistic About Humacyte, Inc. (HUMA): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Humacyte, Inc. (HUMA). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Zacks
News Placeholder
Are Medical Stocks Lagging Agilon Health (AGL) This Year?
Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.
Zacks
News Placeholder
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization
Why Humacyte, Inc. (HUMA) Price Target Was Raised Despite Early-Stage Commercialization...
Yahoo! Finance: News
News Placeholder
Humacyte Reports Q1 2026 Results: Full Earnings Call Transcript
read more...
Benzinga
<
1
2
...
>

Advertisement|Remove ads.